Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06350097
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-04-02
Brief Title:
Phase III Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sponsor:
Organization:
AstraZeneca